Radiation and chemotherapy of parameningeal rhabdomyosarcoma involving the orbit.
Eighteen patients with parameningeal rhabdomyosarcoma (RMS) involving the orbit were treated at Memorial Sloan-Kettering Cancer Center (MSKCC) between July 1971 and October 1983. Fifteen patients were children with a mean age of 6 years and three patients were adults with a mean age of 21 years. In four patients, the primary tumor originated in the orbit, while the remaining 14 had other parameningeal primary sites. The tumors were in a very progressive local stage, with destruction of facial bones in most patients. Six patients were treated with the T2 chemotherapy protocol and 12 received the T6 protocol. The radiation treatment plan for all patients was designed to deliver between 4500 and 7200 rad delivered to the primary tumor over 4 to 16 weeks. Eleven of the 18 patients (61%) are alive and well with a median follow-up time of six years. Two patients died of therapeutic complications and five died of tumor spread with central nervous system involvement. Ocular complications included acute and chronic conjunctival, corneal, lens, and retinal changes, which were less severe than those reported in previous series.
D002386:Cataract / Q000209:etiology / Q000473:pathology; D003131:Combined Modality Therapy; D005128:Eye Diseases / Q000209:etiology / Q000473:pathology; D006801:Humans; D008577:Meningeal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy*; D009918:Orbital Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy*; D011832:Radiation Injuries; D011859:Radiography; D012164:Retinal Diseases / Q000209:etiology / Q000473:pathology; D012208:Rhabdomyosarcoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy*